Patents by Inventor Anlai Wang

Anlai Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
    Publication number: 20250057852
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: July 18, 2024
    Publication date: February 20, 2025
    Inventors: Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Michael Witten, Yao Xu, Hai Fen Ye, Ke Zhang, Peng Zhao, Wenqing Yao
  • Bicyclic Ureas As Kinase Inhibitors
    Publication number: 20240317744
    Abstract: The present application provides bicyclic urea compounds that modulate the activity of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: March 12, 2024
    Publication date: September 26, 2024
    Inventors: Xin Li, Oleg Vechorkin, Yanran Ai, Onur Atasoylu, Hang Thi Dang, Brent Douty, Chunhong He, Peng He, Michael Liang, Minh Nguyen, Evan Styduhar, Anlai Wang, Xiaozhao Wang, Hai Fen Ye, Eddy W. Yue, Ke Zhang, Peng Zhao
  • Bicyclic heterocycles as FGFR inhibitors
    Patent number: 12083124
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: January 26, 2023
    Date of Patent: September 10, 2024
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Michael Witten, Yao Xu, Hai Fen Ye, Ke Zhang, Peng Zhao, Wenqing Yao
  • PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20240287059
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Application
    Filed: September 8, 2023
    Publication date: August 29, 2024
    Inventors: Oleg Vechorkin, Jun Pan, Kai Liu, Alexander Sokolsky, Anlai Wang, Hai Fen Ye, Qinda Ye, Wenqing Yao
  • BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
    Publication number: 20230338389
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: January 26, 2023
    Publication date: October 26, 2023
    Inventors: Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Michael Witten, Yao Xu, Hai Fen Ye, Ke Zhang, Peng Zhao, Wenqing Yao
  • Pyrazolopyridine compounds and uses thereof
    Patent number: 11795166
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: January 7, 2021
    Date of Patent: October 24, 2023
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Jun Pan, Kai Liu, Alexander Sokolsky, Anlai Wang, Hai Fen Ye, Wenqing Yao
  • BICYCLIC AMINE CDK12 INHIBITORS
    Publication number: 20230203010
    Abstract: The present application provides bicyclic amines that are inhibitors of cyclin-dependent kinase 12 (CDK12), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: December 2, 2022
    Publication date: June 29, 2023
    Inventors: Xin Li, Michael Liang, Evan Styduhar, Robert Swyka, Oleg Vechorkin, Anlai Wang, Lin You, Peng Zhao, Ke Zhang, Minh Nguyen
  • Bicyclic heterocycles as FGFR inhibitors
    Patent number: 11607416
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: March 21, 2023
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Michael Witten, Yao Xu, Hai Fen Ye, Ke Zhang, Peng Zhao, Wenqing Yao
  • Bicyclic heterocycles as FGFR inhibitors
    Patent number: 11591329
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 enzyme and are useful in the treatment of FGFR3-associated diseases such as cancer.
    Type: Grant
    Filed: July 8, 2020
    Date of Patent: February 28, 2023
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Chao Qi, Minh Nguyen, Anlai Wang, Wenqing Yao
  • PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS
    Publication number: 20230043959
    Abstract: The present invention provides piperidin-4-y1 azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Application
    Filed: February 17, 2022
    Publication date: February 9, 2023
    Inventors: Taisheng Huang, Chu-Biao Xue, Hui-Yin Li, Qun Li, Anlai Wang, Lingquan Kong, Hai Fen Ye, Wenqing Yao, James D. Rodgers, Stacey Shepard, Haisheng Wang, Lixin Shao
  • Indazole compounds and uses thereof
    Patent number: 11492354
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: November 8, 2022
    Assignee: Incyte Corporation
    Inventors: Alexander Sokolsky, Oleg Vechorkin, Anlai Wang, Qinda Ye, Wenqing Yao
  • Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors
    Patent number: 11229631
    Abstract: The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use. The compounds inhibit the activity of the Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: January 25, 2022
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Chu-Biao Xue, Yun-Long Li, Hao Feng, Jun Pan, Anlai Wang, Ke Zhang, Wenqing Yao, Fenglei Zhang, Jincong Zhuo
  • PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20220017521
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and/or FGFR activity, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity and/or FGFR activity, such as cancer.
    Type: Application
    Filed: August 4, 2021
    Publication date: January 20, 2022
    Inventors: Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Liangxing Wu, Wenqing Yao, Peng Zhao
  • PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20210380581
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Application
    Filed: January 7, 2021
    Publication date: December 9, 2021
    Inventors: Oleg Vechorkin, Jun Pan, Kai Liu, Alexander Sokolsky, Anlai Wang, Hai Fen Ye, Qinda Ye, Wenqing Yao
  • Pyrazolopyrimidine compounds and uses thereof
    Patent number: 11111247
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and/or FGFR activity, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity and/or FGFR activity, such as cancer.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: September 7, 2021
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Liangxing Wu, Wenqing Yao, Peng Zhao
  • Heterocyclic compounds useful as Pim kinase inhibitors
    Patent number: 11053215
    Abstract: The present application is concerned with heterocyclic compounds that inhibit the activity of Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancers and other diseases.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: July 6, 2021
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Yun-Long Li, Alexander Sokolsky, Anlai Wang, Wenyu Zhu, Jincong Zhuo
  • BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
    Publication number: 20210106588
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: October 14, 2020
    Publication date: April 15, 2021
    Inventors: Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Michael Witten, Yao Xu, Hai Fen Ye, Ke Zhang, Peng Zhao, Wenqing Yao
  • Pyrazolopyridine compounds and uses thereof
    Patent number: 10934288
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: March 2, 2021
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Kai Liu, Alexander Sokolsky, Anlai Wang, Hai Fen Ye, Qinda Ye, Wenqing Yao
  • BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
    Publication number: 20210009582
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 enzyme and are useful in the treatment of FGFR3-associated diseases such as cancer.
    Type: Application
    Filed: July 8, 2020
    Publication date: January 14, 2021
    Inventors: Oleg Vechorkin, Chao Qi, Minh Nguyen, Anlai Wang, Wenqing Yao
  • INDAZOLE COMPOUNDS AND USES THEREOF
    Publication number: 20210002288
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Application
    Filed: July 21, 2020
    Publication date: January 7, 2021
    Inventors: Alexander Sokolsky, Oleg Vechorkin, Anlai Wang, Qinda Ye, Wenqing Yao